Clinical Professionals Industry Analytics Report: 2016 Year in Review
To provide our candidates and clients with the best knowledge and advice, the Clinical Professionals Group are devoted to being focused and reactive on the latest changes that affect the industry, from acquisitions to expansions.
Clinical Professionals regularly collaborate with VacancySoft. A company who gather data and publish reports of vacancy analysis of a variety of different industries and countries.
The monthly reports pinpoint sectors and geographical areas that show strong variance within the Life Science sector by focusing on significant increases or decreases in vacancies for a particular business area and/or country.
This month’s report looks takes a look at the previous year; analysing key trends and changes within vacancies in the European Life Science industry.
Clinical Professionals’ CEO, Yvette Cleland has provided some of her insight on the report’s findings:
Patterns of vacancies were similar in the UK and the rest of Europe throughout 2015/16 until the last quarter, which saw a significant drop in vacancies in the UK. This appears to be the building uncertainty around Brexit.
The continued uncertainty around Brexit means it’s difficult to establish any real trend that isn’t in one way or another attributed to Brexit. Whatever the relationship ultimately is, the UK has a strong track record in the life sciences & healthcare sector, with tax incentives, investment & funding, R&D, and other key drivers high on its agenda. We would expect that to continue. The UK accounts for approximately 25% of the EU market and will remain a key market.
Stepping away from the continued Brexit debacle, for which we presently have no answers, the current challenges in the CRO space are a little more interesting. In Reading (home to Quintiles) alone there has been a 32% decrease in live roles in Life Sciences. The overall trend is a 5% decline in CRO vacancies in the UK and an average 26% decline outside the UK. With some 859 clinical trial providers globally and a tightening market, CROs will need to look at other revenue streams or innovations so they can differentiate themselves.
2017 will be a very interesting year for everyone in Life Sciences; until we know what “triggering Article 50” looks like and what the onward journey will be, no real predictions that can be accurately made. I guess the only certain thing is uncertainty.
The report also featured other noteworthy statistics:
You can find the report and other previous editions here: Clinical Professionals Industry Analytics Reports